GHRHR and cancer: Both GH and IGF-1 have also been found to actas potent mitogens in cancers.8 However,the role of these hormones in cancer remains to be fully elucidatedand exploited in a therapeutic context, with GH and IGF-1 targetingstrategies resulting in side effects such as fluid retention, hypertension,and increased body weight.9 Overexpressionof GHRHR and its most prominent splice variant, SV1, has also beenassociated with several types of cancer, including breast,10 prostate,11 thyroid,12 pancreatic,13 andesophageal14 cancers.